Cannabidiol, neuroprotection and neuropsychiatric disorders

Alline C Campos¹,²,*; Manoela V Fogaça¹,²; Andreza B. Sonego¹,²; Francisco S Guimarães¹,²

¹ Department of Pharmacology, Medical School of of Ribeirão Preto, University of São Paulo, Bandeirantes Avenue, 3900, 14049-900, Ribeirão Preto, São Paulo, Brazil.

² Center of Interdisciplinary Research on Applied Neurosciences (NAPNA), University of São Paulo, Brazil.

*Corresponding author

Alline C. de Campos, B.Pharm, M.Sc., Ph.D.
Department of Pharmacology
School of Medicine of Ribeirão Preto
University of São Paulo
3900 Bandeirantes avenue
Ribeirão Preto-SP, Brazil
Phone: +551633153325

Graphical abstract
Abstract

Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid derived from *Cannabis sativa*. It has possible therapeutic effects over a broad range of neuropsychiatric disorders. CBD attenuates brain damage associated with neurodegenerative and/or ischemic conditions. It also has positive effects on attenuating psychotic-, anxiety- and depressive-like behaviors. Moreover, CBD affects synaptic plasticity and facilitates neurogenesis. The mechanisms of these effects are still not entirely clear but seem to involve multiple pharmacological targets. In the present review, we summarized the main biochemical and molecular mechanisms that have been associated with the therapeutic effects of CBD, focusing on their relevance to brain function, neuroprotection and neuropsychiatric disorders.

Keywords: neuropsychiatric disorders; cannabidiol; oxidative stress; endocannabinoids; 5HT1A receptor; PPAR-γ receptor
1. Introduction

Neuropsychiatric disorders are complex medical conditions that affect millions of people worldwide, being one of the most common causes of incapacity [1]. Although these disorders are caused by a complex interaction of several factors, such as genes and the environment [3,4], their specific etiology remains poorly understood. Consequently, patients still have a limited access to effective treatments [4].

In last decade, the research in this area has focused on the neuroplastic cellular processes responsible for brain adaptation as new therapeutic targets for these disorders [5-7]. Common features involving neuroprotective mechanisms (oxidative stress, immune mediators, neurotrophic factors) have been described, together with high levels of comorbidity between apparently different disorders [8-10]. As a possible reflect of these common features, the therapeutic indications of traditional treatments have also expanded. Antidepressants, for example, are the first-line treatment for depression and some anxiety disorders. However, they also possess neuroprotective properties, preventing the formation of amyloid plaques in a transgenic mouse model and humans and having positive effects in stroke [12]. The mechanisms underlying these effects involve multiple targets, such as elevation of brain-derived neurotrophic factor (BDNF) levels [13, 14], reduction of microglia activation, and decreased levels of proinflammatory mediators [15, 16].

Cannabinoids have also emerged as a new class of drugs with potential effects over a broad range of neurodegenerative and psychiatric disorders [17, 18]. The term cannabinoids refer to a heterogeneous group of compounds classified into three main groups: endogenous, synthetic and phytocannabinoids [17, 19]. Phytocannabinoids consist of terpenophenolic substances derived from the Cannabis sativa plant. The plant produces at least 66 compounds, including Δ9-tetrahydrocannabinol (THC), the one
responsible for its main psychological effects, whereas cannabidiol (CBD) is the major non-psychotomimetic compound present in the plant [20, 21].

The investigation of the possible positive impact of CBD in neuropsychiatric disorders began in the 1970s. After a slow progress, this subject has been showing an exponential growth in the last decade (Figure 1). CBD exhibits a broad spectrum of potential therapeutic properties in animal models and humans, including anxiolytic [17, 22], antidepressant [23], neuroprotective [17, 24-28], anti-inflammatory [29-32], and immunomodulatory [33, 34]. Regarding the latter, CBD decreases the production of inflammatory cytokines, the activation of microglial cells [31, 35, 36], and brain leucocytes infiltration in experimental autoimmune encephalitis [35]. Moreover, treatment based on this phytocannabinoid preserves cerebral circulation during ischemic events and reduces vascular changes and neuroinflammation in a model of sepsis-related encephalitis [26, 36-38].

Several clinical trials using CBD alone or in combination with other cannabinoids are under development. For example, the drug is being tested for Schizophrenia and cognitive dysfunction related to Schizophrenia (phase 2), Huntington’s Disease (phase 2), and multiple sclerosis (MS-phase 3). Of note, the GW compound Sativex® showed to provide positive effects for the relief of MS-related spasticity while Epidolex® is currently in phase 3 trial for the treatment of orphan pediatric epilepsy syndrome [39].

CBD also has a better safety profile compared to other cannabinoids, such as THC. For instance, high doses of CBD (up to 1,500 mg/day) are well tolerated in animals and humans [40]. In addition, it does not change heart rate, blood pressure or body temperature, does not induce catalepsy, and does not alter psychomotor or psychological functions like THC [40]. This improved safety profile is probably reflecting its lack of direct agonist properties at cannabinoid receptors [41].
The mechanisms responsible for the wide range of CBD potential neuroprotective effects in neuropsychiatric disorders are not completely understood. New findings obtained in the last decade indicate that they involve multiple pharmacological targets. In the present review, we tried to summarize and discuss the importance of the main targets that have been associated with CBD neuroprotective action (table 1) and its effects on neuropsychiatric disorders.

1.1- The endocannabinoid system

The endocannabinoid system comprises mainly the cannabinoid CB1 and CB2 receptors, their endogenous agonists, the endocannabinoids (ECs) anandamide (AEA) and 2-arachydonoilglycerol (2-AG), and the proteins responsible for their uptake, synthesis, and degradation. Cannabinoid receptors are coupled to a Gi/o protein and, once activated, increase K+ cell influx leading to membrane hyperpolarization [42]. As a consequence, the probability of neurotransmitter release from the pre-synaptic terminal decreases, characterizing the ECs as retrograde messengers [43].

Several cannabinoid compounds have been shown to induce neuroprotection by acting on CB1 and/or CB2 receptors [44-46]. Although numerous in vitro studies suggest that CBD has a very low affinity for CB1 and CB2 receptors [47, 48], some of the effects of this drug seem to involve these receptors. This apparent contradiction could be explained by an in vivo drug action as an antagonist/inverse agonist at cannabinoid receptors or, more probably, by an indirect increase of anandamide levels through inhibition of its metabolism/uptake [49-52]. Corroborating the latter possibility, the CB1 receptor inverse agonist AM251 blocked CBD effects on both extinction and reconsolidation of conditioned fear [53], and on mice marble burying behavior [54].

In a model of newborn hypoxic-ischemic brain damage CBD, in vivo and in vitro, prevented the decrease in the number of viable neurons and attenuated the increase in
excitotoxicity, oxidative stress and inflammation (Table 1) [51, 55]. In brain slices submitted to hypoxic conditions, CBD effects on the production of IL-6, TNF-α, and COX-2 induction were attenuated by AM630, a CB2 antagonist [51]. This response, interestingly, did not depend on a CBD-induced increase in ECs levels [51]. In another study, CBD reduced β-amyloid-induced microglial activation in vitro, a model used to study some of the alterations found in Alzheimer’s disease. It also decreased LPS-induced nitrite generation. Although the first effect depended on CB1 and CB2 receptor, the latter was not affected by pre-treatment with cannabinoid antagonists [56]. Besides CBD alone, its 1:1 combination with Δ(9)-tetrahydrocannabinol (THC) in the phytocannabinoid-based medicine Sativex®) also produced neuroprotective effects through a CB1- and CB2-mediated mechanism in a model of Huntington’s disease [57]. CBD might also facilitate the survival of newborn hippocampal neurons via facilitation of anandamide neurotransmission through CB1 receptors [52, 58].

1.2. 5HT1A receptors

Seven different types of serotonin receptors have been identified so far: one ionotropic and six G-protein coupled. The 5HT1 class is coupled to a Gi/o protein and includes five subtypes: 5HT1A, 5HT1B, 5HT1D, 5HT1E, and 5HT1F. From this family, the 5HT1A is the main receptor related to CBD neuroprotective effects [18]. These receptors are present in pre-synaptic membranes as autosomic receptors and also found post-synaptically in several brain areas [59].

A pioneer in vitro study by Russo and colleagues [60] suggested that CBD could facilitate 5HT1A-mediated neurotransmission by acting as an agonist at these receptors [41]. Following this initial study, our group confirmed that the acute anxiolytic effects of CBD depend on facilitation of 5HT1A-mediated neurotransmission [17, 61]. Recent
findings, however, indicate that CBD is not a 5HT1A receptor agonist as originally proposed. Although not yet clear, its 5HT1A-mediated effects could involve allosteric interactions with the receptor binding site and/or interference with intracellular pathways [62, 63].

Regarding CBD effects on models of neuropsychiatry disorders, CBD peripheral injections attenuated acute autonomic responses evoked by stress, induced anxiolytic and panicolytic-like effects after intra-dorsal periaqueductal gray injections by activating 5HT1A receptors [61, 64-66]. The same 5HT1A receptor-dependent mechanism was observed after CBD injections into the bed nucleus of stria terminalis and prefrontal cortex [67-69]. CBD acute or chronic peripheral injections also induced antidepressant-like effects by activation of 5HT1A receptors [23, 20].

Part of the neuroprotective effects induced by CBD has also been associated with 5HT1A-mediated mechanisms. Pretreatment with the 5HT1A receptor antagonist WAY100635 prevented CBD reduction of brain tissue damage caused by cerebral artery occlusion [38, 71]. Furthermore, Magen and colleagues [72] suggested that 5HT1A receptors mediate CBD positive effects on the cognitive and locomotor deficits observed in a model of encephalopathy in mice, an effect replicated in another model using thioacetamide-induced liver failure [73]. More recently, Pazos and colleagues [55] showed that prevention of hypoxic-induced brain damage by CBD is not only mediated by 5HT1A, but also by CB2 receptors. Moreover, it is possible that the formation of heterodimers between these two receptors could account for CBD effects [55].

1.3- Oxidative stress and Peroxisome Proliferator-Activated Receptor gamma (PPARγ)

Oxidative stress is characterized by an imbalance between the production of reactive oxygen/nitrogen species (ROS/RNS) and antioxidative protection systems in favor of
the oxidant species. An exacerbated production of ROS/RNS can be harmful to the body, since these compounds are highly reactive, with the biomolecules leading to the peroxidation of the polyunsaturated fatty acids, nitration and carbonylation of proteins and oxidation of DNA, leading ultimately to cellular death [74, 75]. In addition to excessive ROS/RNS generation, a reduced activity of the antioxidant system, including its enzymatic components such as superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx), and non-enzymatic ones, such as glutathione (GSH), are also observed [74, 75].

CBD has antioxidant properties that depend on its chemical structure, showing neuroprotective effects by decreasing oxidative parameters and increasing cell viability. It can donate electrons under a variable voltage potential as well as prevent dihydrorhodamine oxidation in the Fenton reaction similarly to the antioxidant butylhydroxytoluene (BHT). Also, CBD protects, in a concentration-related manner, neurons incubated with tert-butyl hydroperoxide. Moreover, it is significantly more effective than other antioxidants (α-tocopherol and ascorbate) in a glutamate toxicity model [76]. Confirming these results, CBD attenuated tyrosine nitration, an indirect measure of the formation of ONOO−, and reduced apoptosis of retinal neurons in rats subjected to intravitreal injection of NMDA [77]. In a diabetic retinopathy model, CBD reduced tyrosine nitration and malondialdehyde (MDA) levels, a measure of lipid peroxidation, as well as decreased neural cell death [78]. These effects were also observed in in vitro models of Alzheimer’s disease and multiple sclerosis. CBD pretreatment reduced ROS accumulation, lipid peroxidation, caspase-3 levels and DNA fragmentation in PC12 cells stimulated by β-amyloid [79]. Regarding the culture of oligodendrocyte progenitor cells, CBD reduced ROS production and cell death induced by H2O2 [80]. In contrast to these results, Massi et al. [81] observed that CBD had anti-
proliferative effects in human glioma cells by producing ROS and depleting GSH stocks. However, in non-transformed glial cells, the drug did not induce oxidative stress. Other cannabinoids such as anandamide behave in the same way [82]. Thus, the antioxidant or pro-oxidant properties of cannabinoids seem to depend on biochemical and cellular features of tumor versus non-tumor cells, such as differences in signal transduction and/or redox state [81].

Besides the direct effects of CBD on the production of ROS/RNS, this phytocannabinoid also increases the expression of components of antioxidative systems. For example, CBD up-regulated SOD mRNA levels in the substantia nigra of rats unilaterally lesioned with 6-hydroxydopamine, a Parkinson’s disease model [44], and in the caudate-putamen of rats treated with 3-nitropropionic acid, a Huntington’s disease model [83]. In addition to ameliorating oxidative stress by acting as a scavenger of oxidant species [76], CBD could also act, at least in part, through receptor-dependent mechanisms, such as the peroxisome proliferator-activated receptor gamma (PPARγ) [18, 84]. PPARs are a nuclear hormone receptors family that have their activities regulated by steroids and metabolites derived from lipid. So far, three different PPAR isoforms (PPARα, PPARβ, also called δ, and PPARγ) have been described [85]. Several pieces of evidence suggested that PPARγ receptors could be an attractive drug target for inflammatory-associated neuropsychiatric disorders, including neurodegenerative diseases [29, 86, 87]. PPARγ receptors seem to be involved in cellular proliferation, apoptosis and reduction of damage induced by ROS. Its activation inhibits the transcription of pro-inflammatory genes, preventing the NF-κB signaling pathway [86, 87].

CBD prevents amyloid-β-induced neuronal death by its ability to scavenge ROS [88] and reduce oxidative stress. PPARγ seems to be relevant for these effects by interacting
with the transcription factor nuclear factor-erythroid 2-related Factor 2 (Nrf-2) [18]. Nrf-2 and PPARγ regulate each other. There are binding sites for Nrf-2 (AREs, antioxidant response elements) in the PPARγ promoter and PPAR responsive elements (PPERs) in the Nrf-2 promoter [89]. Moreover, gene expression associated with oxidative stress is controlled by Nrf-2 [90]. Recently, we have found that CBD prevented microglial activation by LPS in vitro by activating PPARγ, an effect that was associated with impairment of the NF-κB pathway [91].

In addition, using a murine genetic model of Alzheimer’s Disease, Esposito and coworkers [29] suggested the PPARγ-mediated effect of CBD could also involve the decrease of activated glial cells and neuronal death, and facilitation of hippocampal neurogenesis. Recently, the same group showed that CBD increased neuronal survival by reducing apoptosis and decreasing amyloid precursor protein levels through activation of PPARγ receptors [92].

1.4- Immune mediators, BDNF, and other related mechanisms

The beneficial effects of CBD on brain disorders have also been associated with its capacity of modulating pro-inflammatory cytokines and BDNF expression, and interfering with intracellular pathways involved in neuronal fate [17, 18]. In a model of hepatic encephalopathy, CBD chronic treatment ameliorates cognitive and locomotor activity by restoring brain BDNF levels and decreasing mRNA expression of the type-1 TNF-α receptors [37]. In another study, using an intravital microscopy technique, CBD decreased leucocyte migration to the central nervous system and TNF-α expression induced by the previous administration of LPS [37]. Lower brain levels of BDNF and increased pro-inflammatory cytokines were correlated with poor cognitive performance in rats submitted to an experimental model of meningitis. These effects were attenuated by CBD treatment [93]. CBD also increased BDNF levels in the
hippocampus of rats subjected to a model of amphetamine-induced oxidative stress, a proposed model to study mania [94]. Recently, Campos and colleagues [24] suggested that the neuroprotective effects of CBD in a murine model of cerebral malaria are associated with its anti-inflammatory activity (by decreasing TNFα and IL1-6 levels in the prefrontal cortex and hippocampus) and its capacity for up-regulating BDNF expression in the hippocampus.

In addition, CBD decreased microglia activation in murine models of Alzheimer’s disease and schizophrenia [30, 95]. In experimental autoimmune encephalomyelitis (EAE), a murine model the mimic some aspects of multiple sclerosis, CBD decreased microglial cells activation by regulating STAT1/STAT3 balance and Th17 proliferation and function [35, 90] CBD also decreased IL-6 and IL-17 release and reduced the severity of EAE [20]. Recently, Kozela and coworkers [96] suggested that CBD immunoregulatory effects rely on a strong up-regulation of inhibitory molecules on CD4+CD25− T cells.

During inflammatory conditions, the activation of mitogen-activated protein kinases, such as p38/MAP-kinase, might lead to the production of pro-inflammatory mediators. Thereby CBD, through its antioxidant properties, could inhibit the phosphorylation of p38, reducing the neurotoxic effects of an uncontrolled immune response [88]. CBD also reverts tau hyperphosphorylation through the blocked of the GSK3-beta pathway [97]. Moreover, in neural precursor cells cultures, this phytocannabinoid increased the expression, in a time-dependent manner, of the phosphorylated forms ERK1/2 and AKT. Given the positive effects of CBD on adult hippocampal neurogenesis [52, 15, 58], these observations suggest that the pro-proliferative and pro-survival effects of CBD involve a dynamic and complex process of recruiting these intracellular pathways. Accordingly, the neuroprotective effect of repeated CBD administration on brain
changes caused by chronic unpredictable stress (reduced neurogenesis and dendrite remodeling) or pilocarpine-induced seizures seem to be associated with a facilitation of autophagy, a mechanism essential for cell health [98, Hosseinzadeh et al., 2016]. This possible CBD mechanism could also be important for its antitumor effects [100].

1.5- Inhibition of adenosine uptake

Enhancement of adenosine signaling, by inhibition of its uptake, has been proposed to mediate part of the anti-inflammatory, immunosuppressive, neuroprotective and behavioral effects of CBD [101]. Consistent with this proposal, CBD increased extracellular levels of adenosine [102]. Moreover, A2A receptor antagonists prevented CBD effects in a model of multiple sclerosis [30], the neuroprotection observed in brain slices of newborn mice after hypoxia and glucose deprivation [51], and rat microglial activation by LPS [103]. It failed, however, to block CBD neuroprotective effect against 3-nitropropionic acid [83]. Behaviorally, adenosine A1 or A2A receptor antagonists prevented CBD memory effects in adult zebrafish [104]. Indirect activation of A1 receptors also seems to be involved in CBD modulation of the pain pathways [105].

2.0- Conclusions and perspectives

As for other effects of this remarkable phytocannabinoid [17, 113], the neuroprotective properties of CBD seem to depend on several cannabinoid-dependent and independent mechanisms (Figure 2). Despite the mechanisms involved, however, the preclinical evidence reviewed here, associated with the already reported safety profile of CBD in humans [22, 40], clearly indicate that CBD represents a new opportunity for the treatment of several brain disorders (such as neurodegenerative and neuropsychiatric) where neuronal loss or damage plays a significant role.
3.0- References


[118] M. Moreno-Martet, F. Espejo-Porras, J. Fernández-Ruiz, E. de Lago. Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex® -like combination of phytocannabinoids: interest

Figure 1. Number of published papers in PubMed describing possible therapeutic effects of cannabidiol in neuropsychiatric disorders since 1970. The occasion of the first publication associating CBD effects with specific disorders is also displayed in the figure [references: 70, 114-119]
Figure 2. Possible mechanisms responsible for the neuroprotective effects of cannabidiol
Table 1 – Neuroprotective effects of CBD in different models and their suggested mechanisms of action
<table>
<thead>
<tr>
<th>Model/Method</th>
<th>Treatment schedule</th>
<th>CBD dose/concentration range</th>
<th>CBD effect</th>
<th>Suggested mechanism of action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newborn hypoxic-ischemic brain damage (HI)</td>
<td>15-min pre-incubation</td>
<td>0.1 to 1000 µM</td>
<td>Reduced acute and apoptotic HI brain damage; Reduced glutamate, IL-6 concentration and TNFa, COX-2 and iNOS expression</td>
<td>CB₂ and A₂A receptors</td>
</tr>
<tr>
<td>Newborn hypoxic-ischemic brain damage (HI)</td>
<td>30 min after HI</td>
<td>1 mg/kg, i.p.</td>
<td>Prevented the decrease in the number of viable neurons and the increase in excitotoxicity, oxidative stress and inflammation</td>
<td>CB₂ and 5HT₁A receptors</td>
</tr>
<tr>
<td>Striatal lesions caused by 3-nitropropionic acid (3NP)</td>
<td>3NP (10 mg/kg, twice a day) and/or CBD injections for 5 days, i.p.</td>
<td>5 mg/kg, i.p.</td>
<td>Reversed 3NP-induced reductions in GABA contents and mRNA levels for substance P, neuronal-specific enolase and superoxide dismutase(SOD)-2; partially attenuated SOD-1 and proenkephalin mRNA.</td>
<td>Independent of CB₁, TRPV₁ and A₂A receptors</td>
</tr>
<tr>
<td>Middle cerebral artery (MCA) occlusion</td>
<td>Immediately before and 3 or 4h after MCA occlusion; 1 and 2h after reperfusion, i.p.</td>
<td>0.1, 1 and 3 mg/kg, i.p.</td>
<td>Suppressed the decrease in cerebral blood flow by the failure of cerebral microcirculation after reperfusion; inhibited myeloperoxidase (MPO) activity in neutrophils; reduced the number of MPO-immunopositive cells</td>
<td>Independent of CB₁ receptors</td>
</tr>
<tr>
<td>6-hydroxydopamine toxicity in vivo and in vitro</td>
<td>2 weeks/daily</td>
<td>3 mg/kg, i.p.</td>
<td>Attenuated the reduction of tyrosine hydroxylase activity in the lesioned striatum and the reduction of this enzyme in the substantia nigra; protected against Aβ-evoked cell viability and from BV-2-conditioned media activated via LPS</td>
<td>NS</td>
</tr>
<tr>
<td>Amyloid β-induced neuronal toxicity and microglial-conditioned media-based neurotoxicity in vitro</td>
<td>24-h incubation</td>
<td>10 µM</td>
<td>Protected against Aβ-evoked cell viability and from BV-2-conditioned media activated via LPS</td>
<td>NS</td>
</tr>
<tr>
<td>Amyloid β-induced toxicity and tert-butyl hydroperoxide-induced oxidative stress</td>
<td>15 min pre-incubation before Aβ or sAβ addition/ 24-h incubation for oxidative stress analysis</td>
<td>0.01-10 µM</td>
<td>Improved cell viability in response to tert-butyl hydroperoxide</td>
<td>NS</td>
</tr>
<tr>
<td>LPS-induced NO generation; microglial cell migration Morris water maze test in β amyloid-injected mice,</td>
<td>24-h incubation 3 weeks: first week treated daily; second and third weeks treated 3 times/week, i.p.</td>
<td>10-1000 nM</td>
<td>Inhibited NO generation and ATP-induced intracellular calcium increase in cultured microglia; promoted microglial cell migration; prevented Aβ-induced learning deficit and IL-6 mRNA expression</td>
<td>Some of the in vitro effects were mediated by A₂A, CB and CB₂ receptors</td>
</tr>
<tr>
<td>Experimental autoimmune encephalomyelitis (EAE)</td>
<td>Before anticipated relapse</td>
<td>5 and 10 mg/kg</td>
<td>Slowed the accumulation of disability from the inflammatory penumbra during relapsing EAE</td>
<td>Blockage of voltage-gated calcium channels</td>
</tr>
<tr>
<td>Condition</td>
<td>Treatment</td>
<td>Concentration</td>
<td>Effect</td>
<td>Mechanism</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------</td>
<td>---------------</td>
<td>--------</td>
<td>-----------</td>
</tr>
<tr>
<td>Paclitaxel (PAC)-induced mechanical sensivity</td>
<td>Before each of the four PAC injections (On experimental days 1, 3, 5 and 7)</td>
<td>2.5, 5 and 10 mg/kg, i.p.</td>
<td>Prevented the PAC-induced mechanical sensivity</td>
<td>5HT\textsubscript{1}A receptors dependent CB\textsubscript{1} and CB\textsubscript{2} receptors independent</td>
</tr>
<tr>
<td>N-metil-D-aspartate (NMDA)-induced retinal neurotoxicity</td>
<td>Immediately before intravitreal injection of NMDA (80 nmol/eye)</td>
<td>2 mg/kg, i.v.</td>
<td>Attenuated the NMDA-induced tyrosine nitration and reduced NMDA-induced apoptosis</td>
<td>Antioxidant: reduction of oxidative and nitrative stress</td>
</tr>
<tr>
<td>Diabetic retinopathy</td>
<td>Every 2 days for 2 or 4 weeks</td>
<td>10 mg/kg, i.p.</td>
<td>Reduced neural cell death, malondialdehyde (MDA) levels, 2,7'-dichlorofluorescein (DCF) fluorescence, tyrosine nitration, VEGF expression, ICAM-1 expression and TNF-α levels; blocked the increases of phosphorylation of p38</td>
<td>Antioxidant: reduction of oxidative and nitrative stress</td>
</tr>
<tr>
<td>amyloid β -induced toxicity</td>
<td>24-h incubation</td>
<td>10\textsuperscript{-7}-10\textsuperscript{-4}M</td>
<td>Increased cell survival; decreased ROS production, MDA levels, caspase 3 levels and DNA fragmentation</td>
<td>Antioxidant: reduction of oxidative and nitrative stress</td>
</tr>
<tr>
<td>H\textsubscript{2}O\textsubscript{2}-induced oxidative stress</td>
<td>2-h incubation</td>
<td>1 μM</td>
<td>Decreased cell death and DCF fluorescence</td>
<td>Antioxidant: reduction of oxidative stress</td>
</tr>
<tr>
<td>6-hydroxydopamine toxicity</td>
<td>2 weekly</td>
<td>3 mg/kg</td>
<td>Recovered 6-hydroxydopamine-induced dopamine depletion and upregulated mRNA levels of SOD in the substantia nigra</td>
<td>Antioxidant</td>
</tr>
<tr>
<td>Encephalopathy (bile duct ligation)</td>
<td>4 weeks</td>
<td>5mg/Kg</td>
<td>Improve of cognition and motor activity. Restores BDNF levels</td>
<td>5HT\textsubscript{1}A</td>
</tr>
<tr>
<td>Encephalopathy (thioacetamide)</td>
<td>Single dose</td>
<td>5mg/Kg</td>
<td>Cannabidiol restored liver function, normalizes 5-HT levels and improves brain pathology</td>
<td>5HT-dependent mechanism</td>
</tr>
<tr>
<td>β amyloid-induced neurotoxicity</td>
<td>incubation</td>
<td>10μM</td>
<td>Inhibited of phosphorylated form of p38 MAP kinase and transcription factor nuclear factor-kappaB activation</td>
<td>Antioxidant</td>
</tr>
<tr>
<td>Pro-neurogenic</td>
<td>4 weeks</td>
<td>ND</td>
<td>Increased proliferation, survival and maturation of new neurons</td>
<td>CB\textsubscript{1}</td>
</tr>
<tr>
<td>Genetic model of Alzheimer’s Disease</td>
<td>15 days</td>
<td>10mg/Kg</td>
<td>Decreased glosis, neuronal death and facilitates neurogenesis</td>
<td>PPAR\textsubscript{γ}</td>
</tr>
<tr>
<td>amyloid β -induced neurotoxicity</td>
<td>1 week</td>
<td>10mg/Kg</td>
<td>Decreased IL-1beta, GFAP and iNOS expression</td>
<td>NS</td>
</tr>
<tr>
<td>amyloid β -induced neurotoxicity</td>
<td>24h</td>
<td>100nM</td>
<td>Decreased amyloid- β production</td>
<td>PPAR\textsubscript{γ}</td>
</tr>
<tr>
<td>LPS-induced neurotoxicity</td>
<td>Single dose</td>
<td>3mg/Kg</td>
<td>blocked LPS-induced increase in TNF-alpha, COX-2 and blood brain barrier disruption.</td>
<td>NS</td>
</tr>
<tr>
<td>Pneumococcal meningitis</td>
<td>9 days</td>
<td>10mg/Kg</td>
<td>Prevented cognitive impairment, decreases TNF-alpha and IL6 in the brain.</td>
<td>NS</td>
</tr>
<tr>
<td>Amphetamine-induced oxidative stress</td>
<td>2 weeks</td>
<td>60mg/Kg</td>
<td>Decreased of carbonyl groups and prevents amphetamine-induced decreased BDNF expression.</td>
<td>Oxidative stress</td>
</tr>
<tr>
<td>Stress-reduced neurogenesis</td>
<td>2 weeks</td>
<td>100n-30mg/Kg</td>
<td>Increased survival, differentiation and maturation</td>
<td>FAAH, CB1/CB2</td>
</tr>
<tr>
<td>NMDA- agonist induce psychosis</td>
<td>2 weeks</td>
<td>30-60mg/Kg</td>
<td>Decreased microglia activation</td>
<td>NS</td>
</tr>
<tr>
<td>LPS-induced microglia activation</td>
<td>2h</td>
<td>10μM</td>
<td>Blocked LPS-induced STAT1 activation</td>
<td>NF-κB and IFNβ-dependen pathways</td>
</tr>
<tr>
<td>encephalitogenic T cells</td>
<td>18h</td>
<td>5μM</td>
<td>Decreased Th17 activity, induction of CD4+CD25+CD69+LAG3+</td>
<td>NS</td>
</tr>
<tr>
<td>Cerebral malaria</td>
<td>7 days</td>
<td>30mg/Kg</td>
<td>Increased survival, reduce cognitive impairment, decrease IL-6 and TNF, increase BDNF</td>
<td>NS</td>
</tr>
</tbody>
</table>

NS: not studied.